

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ezban et al.

Application No.: To be assigned

Group Art Unit: To be assigned

Filed: January 14, 2002

Examiner: To be assigned

For: Use of FVIIa or a Tissue Factor Antagonist for Regulating Gene Expression and Cell Migration or Chemotaxis

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, DC 20231

Sir:

Before the above-captioned application is taken up for examination, entry of the following amendment is respectfully requested:

IN THE CLAIMS:


Please cancel claims 1-16 without prejudice or disclaimer.

REMARKS

Entry of this amendment is respectfully requested. In this amendment, claims 1-16 are cancelled without prejudice. No new matter is added. Accordingly, claims 17-22 are pending and at issue. It is believed that the claims are in condition for allowance, and a determination to that effect is earnestly solicited.

Respectfully submitted,

Date: January 14, 2002



Reza Green, Reg. No. 38,475
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE